Publications by authors named "Robert Jenke"

Claim this Profile
E
ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancer.
Robert Jenke, Theresa Heinrich, Florian Lordick, Achim Aigner

Cell Death Discov· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies.
Tamara Zenz, Robert Jenke, René Thieme, Tim Kahl, Hannes Borchardt

Cancer Res Treat· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat.
Tamara Zenz, Robert Jenke, Denys Oliinyk, Sandra Noske, René Thieme

Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes.
Leoni Lorenz, Tamara Zenz, Denys Oliinyk, Florian Meier-Rosar, Robert Jenke

Pharmaceuticals (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer.
Robert Jenke, Denys Oliinyk, Tamara Zenz, Justus Körfer, Linda Schäker-Hübner

Biochem Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6.
Maximilian Walther, Robert Jenke, Achim Aigner, Alexander Ewe

Eur J Pharm Biopharm· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.
Linda Schäker-Hübner, Reza Haschemi, Thomas Büch, Fabian B Kraft, Birke Brumme, Robert Jenke

ChemMedChem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Robert Jenke, Nina Reßing, Finn K Hansen, Achim Aigner, Thomas Büch

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy.
Daniela Gutsch, Robert Jenke, Thomas Büch, Achim Aigner

Cells· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.
Robert Jenke, Miriam Holzhäuser-Rein, Stefanie Mueller-Wilke, Florian Lordick, Achim Aigner

Int J Mol Sci· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis